Form 8-K GYRE THERAPEUTICS, INC. For: Jun 01

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586882.html

Form 8-K GYRE THERAPEUTICS, INC. For: Jun 01

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586882.html

Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm

Wed, 27 May 2026 20:01:00 -0400

Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) ("Gyre") on behalf of the company's long-term shareholders.

The investigation seeks to determine whether Gyre and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.  

Gyre shareholders who would like to learn more about this investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229 - 0750, by email at abell@kaskelalaw.com, or by filling out our online form at:

Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm

Wed, 27 May 2026 20:01:00 -0400

Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) ("Gyre") on behalf of the company's long-term shareholders.

Form 4 GYRE THERAPEUTICS, INC. For: May 22 Filed by: Ye Weiguo

Wed, 27 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260527/26557617.html

Form 4 GYRE THERAPEUTICS, INC. For: May 22 Filed by: Ye Weiguo

Wed, 27 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260527/26557617.html

Form 4 GYRE THERAPEUTICS, INC. For: May 20 Filed by: Ye Weiguo

Fri, 22 May 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260522/26543166.html

Form 4 GYRE THERAPEUTICS, INC. For: May 20 Filed by: Ye Weiguo

Fri, 22 May 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260522/26543166.html

Form 4 GYRE THERAPEUTICS, INC. For: May 14 Filed by: Zhang Ping

Wed, 20 May 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260520/26530079.html

Form 4 GYRE THERAPEUTICS, INC. For: May 14 Filed by: Zhang Ping

Wed, 20 May 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260520/26530079.html

Form 4 GYRE THERAPEUTICS, INC. For: May 18 Filed by: Ye Weiguo

Wed, 20 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260520/26528096.html

Form 4 GYRE THERAPEUTICS, INC. For: May 18 Filed by: Ye Weiguo

Wed, 20 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260520/26528096.html

Form 4 GYRE THERAPEUTICS, INC. For: May 14 Filed by: Ye Weiguo

Mon, 18 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260518/26513553.html

Form 4 GYRE THERAPEUTICS, INC. For: May 14 Filed by: Ye Weiguo

Mon, 18 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260518/26513553.html

Form 8-K GYRE THERAPEUTICS, INC. For: May 14

Thu, 14 May 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260514/26496807.html

Form 8-K GYRE THERAPEUTICS, INC. For: May 14

Thu, 14 May 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260514/26496807.html

Form 8-K GYRE THERAPEUTICS, INC. For: May 12

Tue, 12 May 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260512/26479156.html

Form 8-K GYRE THERAPEUTICS, INC. For: May 12

Tue, 12 May 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260512/26479156.html

Gyre Therapeutics receives NMPA acceptance for liver fibrosis drug application

Tue, 12 May 2026 16:06:03 -0400

Gyre Therapeutics Inc. (NASDAQ: GYRE) announced that China's National Medical Products Administration has accepted its New Drug Application for F351 (hydronidone) to treat chronic hepatitis B-induced liver fibrosis.

The Center for Drug Evaluation accepted the application after previously granting priority review status for F351 in March. Gyre submitted the application through its majority-owned subsidiary Gyre Pharmaceuticals Co., Ltd.

"This NDA is our third submission accepted for review by the NMPA, and the first one for our F351 program," said Dr. Ying Luo, President and Chief Executive Officer of Gyre Therapeutics.

F351 is a modified derivative of pirfenidone designed to target the TGF-β1 signaling

Gyre Therapeutics receives NMPA acceptance for liver fibrosis drug application

Tue, 12 May 2026 16:06:03 -0400

"This NDA is our third submission accepted for review by the NMPA, and the first one for our F351 program," said Dr. Ying Luo, President and Chief Executive Officer of Gyre Therapeutics.

F351 is a modified derivative of pirfenidone designed to target the TGF-β1 signaling

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Tue, 12 May 2026 16:05:00 -0400

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for F351 (hydronidone) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). The acceptance comes after the NMPA previously granted priority review status for F351 in March after

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Tue, 12 May 2026 16:05:00 -0400

Form 144 GYRE THERAPEUTICS, INC. Filed by: Ye Weiguo

Mon, 11 May 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260511/26464950.html

Form 144 GYRE THERAPEUTICS, INC. Filed by: Ye Weiguo

Mon, 11 May 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260511/26464950.html

Form 10-Q GYRE THERAPEUTICS, INC. For: Mar 31

Fri, 08 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260508/26461344.html

StreetInsider.com News Articles

Form 8-K GYRE THERAPEUTICS, INC. For: Jun 01

Form 8-K GYRE THERAPEUTICS, INC. For: Jun 01

Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm

Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm

Form 4 GYRE THERAPEUTICS, INC. For: May 22 Filed by: Ye Weiguo

Form 4 GYRE THERAPEUTICS, INC. For: May 22 Filed by: Ye Weiguo

Form 4 GYRE THERAPEUTICS, INC. For: May 20 Filed by: Ye Weiguo

Form 4 GYRE THERAPEUTICS, INC. For: May 20 Filed by: Ye Weiguo

Form 4 GYRE THERAPEUTICS, INC. For: May 14 Filed by: Zhang Ping

Form 4 GYRE THERAPEUTICS, INC. For: May 14 Filed by: Zhang Ping

Form 4 GYRE THERAPEUTICS, INC. For: May 18 Filed by: Ye Weiguo

Form 4 GYRE THERAPEUTICS, INC. For: May 18 Filed by: Ye Weiguo

Form 4 GYRE THERAPEUTICS, INC. For: May 14 Filed by: Ye Weiguo

Form 4 GYRE THERAPEUTICS, INC. For: May 14 Filed by: Ye Weiguo

Form 8-K GYRE THERAPEUTICS, INC. For: May 14

Form 8-K GYRE THERAPEUTICS, INC. For: May 14

Form 8-K GYRE THERAPEUTICS, INC. For: May 12

Form 8-K GYRE THERAPEUTICS, INC. For: May 12

Gyre Therapeutics receives NMPA acceptance for liver fibrosis drug application

Gyre Therapeutics receives NMPA acceptance for liver fibrosis drug application

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Form 144 GYRE THERAPEUTICS, INC. Filed by: Ye Weiguo

Form 144 GYRE THERAPEUTICS, INC. Filed by: Ye Weiguo

Form 10-Q GYRE THERAPEUTICS, INC. For: Mar 31